CY1124952T1 - Αλατα παραγωγων πυρρολοτριαζινης χρησιμα ως αναστολεις ταμ - Google Patents

Αλατα παραγωγων πυρρολοτριαζινης χρησιμα ως αναστολεις ταμ

Info

Publication number
CY1124952T1
CY1124952T1 CY20221100036T CY221100036T CY1124952T1 CY 1124952 T1 CY1124952 T1 CY 1124952T1 CY 20221100036 T CY20221100036 T CY 20221100036T CY 221100036 T CY221100036 T CY 221100036T CY 1124952 T1 CY1124952 T1 CY 1124952T1
Authority
CY
Cyprus
Prior art keywords
salts
derivatives useful
pyrrolotriazine derivatives
phenyl
inhibitors
Prior art date
Application number
CY20221100036T
Other languages
English (en)
Inventor
Zhongjiang JIA
Yongzhong Wu
Yongchun Pan
Jiacheng Zhou
Qun Li
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of CY1124952T1 publication Critical patent/CY1124952T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα αίτηση παρέχει μορφές άλατος Ν-(4-(4-Αμινο-7-(1-ισοβουτυρυλπιπεριδιν-4-υλ)πυρρολο[1,2-f][1,2,4]τριαζιν-5-υλ)φαινυλ)-1-ισοπροπυλ-2,4-διοξο-3-(πυριδιν-2-υλ)-1,2,3,4-τετραϋδροπυριμιδινο-5-καρβοξαμιδίου (Ι) και Ν-(4- (4-Αμινο-7-(1-ισοβουτυρυλπιπεριδιν-4-υλ)πυρρολο[1,2-f][1,2,4]τριαζιν-5-υλ)φαινυλ)-1-ισοπροπυλ-2,4-διοξο-3-φαινυλ-1,2,3,4-τετραϋδροπυριμιδινο-5-καρβοξαμιδίου (II), οι οποίες είναι χρήσιμες ως αναστολείς κινασών ΤΑΜ, καθώς επίσης μεθόδους και ενδιάμεσα που σχετίζονται με αυτές.
CY20221100036T 2017-09-27 2022-01-17 Αλατα παραγωγων πυρρολοτριαζινης χρησιμα ως αναστολεις ταμ CY1124952T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762564070P 2017-09-27 2017-09-27
US201862714196P 2018-08-03 2018-08-03
PCT/US2018/052925 WO2019067594A1 (en) 2017-09-27 2018-09-26 SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS

Publications (1)

Publication Number Publication Date
CY1124952T1 true CY1124952T1 (el) 2023-01-05

Family

ID=63794769

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100036T CY1124952T1 (el) 2017-09-27 2022-01-17 Αλατα παραγωγων πυρρολοτριαζινης χρησιμα ως αναστολεις ταμ

Country Status (33)

Country Link
US (3) US10633387B2 (el)
EP (2) EP3988552A1 (el)
JP (2) JP7504791B2 (el)
KR (1) KR20200088308A (el)
CN (1) CN111386273B (el)
AU (2) AU2018342471B2 (el)
BR (1) BR112020006145A2 (el)
CA (1) CA3077308A1 (el)
CL (2) CL2020000791A1 (el)
CO (1) CO2020005009A2 (el)
CR (1) CR20200179A (el)
CY (1) CY1124952T1 (el)
DK (1) DK3687996T3 (el)
EC (1) ECSP20021655A (el)
ES (1) ES2904458T3 (el)
GE (1) GEP20227429B (el)
HU (1) HUE057190T2 (el)
IL (1) IL273579A (el)
JO (1) JOP20200081A1 (el)
LT (1) LT3687996T (el)
MA (1) MA50655B1 (el)
MD (1) MD3687996T2 (el)
MX (1) MX2020003375A (el)
PE (1) PE20210002A1 (el)
PH (1) PH12020550143A1 (el)
PL (1) PL3687996T3 (el)
PT (1) PT3687996T (el)
RS (1) RS62872B1 (el)
SA (1) SA520411638B1 (el)
SG (1) SG11202002821UA (el)
SI (1) SI3687996T1 (el)
TW (1) TWI821200B (el)
WO (1) WO2019067594A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
TWI753892B (zh) 2016-03-28 2022-02-01 美商英塞特公司 作為ｔａｍ抑制劑之吡咯并三嗪化合物
ES2975336T3 (es) 2016-12-22 2024-07-04 Novartis Ag Moduladores del receptor NMDA y usos de los mismos
MX2020003375A (es) 2017-09-27 2020-08-03 Incyte Corp Sales de inhibidores de macrofagos asociados a tumores (tam).
TWI832871B (zh) 2018-06-29 2024-02-21 美商英塞特公司 Axl/mer 抑制劑之調配物
PE20210948A1 (es) 2018-08-03 2021-05-24 Cadent Therapeutics Inc Moduladores del receptor nmda heteroaromatico y usos de los mismos
US20210275666A1 (en) 2020-03-06 2021-09-09 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2022007921A1 (zh) * 2020-07-10 2022-01-13 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
CN115028648B (zh) * 2021-03-03 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
EP4371978A1 (en) * 2021-07-13 2024-05-22 Nippon Soda Co., Ltd. Method for producing uracil compound

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02002938A (es) 1999-09-17 2004-12-06 Abbott Gmbh & Co Kg Inhibidores de cinasa como agentes agentes terapeuticos.
HU230396B1 (hu) 2000-06-28 2016-04-28 Smithkline Beecham Plc Nedves őrlési eljárás
WO2004035580A1 (en) 2002-10-21 2004-04-29 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
WO2005025515A2 (en) 2003-09-12 2005-03-24 California Institute Of Technology Proteasome pathway inhibitors and related methods
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
SI1951724T1 (sl) 2005-11-17 2011-09-30 Osi Pharmaceuticals Llc Kondenzirani biciklični mTOR inhibitorji
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
EP1957485B1 (en) 2005-12-02 2013-02-13 Bayer HealthCare, LLC Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
ES2562428T3 (es) 2005-12-15 2016-03-04 Rigel Pharmaceuticals, Inc. Inhibidores de cinasa y sus usos
MX2008013110A (es) 2006-04-12 2009-03-06 Vertex Pharma 4-5-dihidro-[1,2,4]triazolo[4,3-f]pteridinas como inhibidores de la proteina-cinasa plk1 para el tratamiento de trastornos proliferativos.
US20090253718A1 (en) 2006-04-25 2009-10-08 Astex Therapeutics Limited Pharmaceutical Compounds
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
EP2102210B1 (en) 2006-12-14 2011-02-09 Vertex Pharmceuticals Incorporated Compounds useful as protein kinase inhibitors
PT2078010E (pt) 2006-12-29 2014-05-07 Rigel Pharmaceuticals Inc Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl
EP2074115B1 (en) 2006-12-29 2018-03-07 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
WO2008083353A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
CA2695753A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2215085B1 (en) 2007-10-25 2011-09-07 AstraZeneca AB Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
WO2009054864A1 (en) 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
EP2262772B8 (en) 2008-04-16 2013-03-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as axl kinase inhibitors
AU2009271658B2 (en) 2008-06-23 2014-04-10 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール
PT2328888E (pt) 2008-07-09 2013-01-29 Rigel Pharmaceuticals Inc Triazóis bicíclicos em ponte substituídos com heteroarilos úteis como inibidores axl
WO2010014755A1 (en) 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
US20100075973A1 (en) 2008-08-28 2010-03-25 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
TW201041892A (en) 2009-02-09 2010-12-01 Supergen Inc Pyrrolopyrimidinyl Axl kinase inhibitors
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
NZ599342A (en) 2009-09-25 2014-04-30 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
TWI643857B (zh) 2010-03-10 2018-12-11 英塞特公司 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
JP5752232B2 (ja) 2010-03-31 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
CN102471342A (zh) 2010-05-05 2012-05-23 沃泰克斯药物股份有限公司 用作PKC-θ抑制剂的4取代的吡唑并吡啶类
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
RU2014118677A (ru) 2010-10-08 2015-11-20 Элан Фармасьютикалз, Инк. Ингибиторы киназ типа polo
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
ES2590778T3 (es) 2011-02-28 2016-11-23 Calitor Sciences, Llc Compuestos de quinolina sustituida
EP2688887B1 (en) 2011-03-23 2015-05-13 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
ES2759615T3 (es) 2011-04-01 2020-05-11 Univ Utah Res Found Análogos de N-fenilpirimidina-2-amina sustituidos como inhibidores de la quinasa AXL
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
CA2846652C (en) 2011-09-02 2019-11-05 Incyte Corporation Heterocyclylamines as pi3k inhibitors
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
JP2014532060A (ja) 2011-10-03 2014-12-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 癌を治療するためのピロロピリミジン化合物
ES2614824T3 (es) 2011-11-14 2017-06-02 Ignyta, Inc. Derivados de uracil como inhibidores de la quinasa axl y c-met
US8993756B2 (en) 2011-12-06 2015-03-31 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
JP6006241B2 (ja) 2012-01-31 2016-10-12 第一三共株式会社 ピリドン誘導体
BR112014000049A2 (pt) 2012-03-27 2017-02-07 Bayer Ip Gmbh pirrolotriazinas substituídas com hidroximelilarilo e sua utilização
WO2013162061A1 (ja) 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
AU2013312477B2 (en) 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN104995192A (zh) 2012-09-26 2015-10-21 加利福尼亚大学董事会 Ire1的调节
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
CN104918945B (zh) 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
CN104936963B (zh) 2012-11-20 2017-11-28 普罗齐纳斯有限公司 作为蛋白激酶抑制剂的硫醚衍生物
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
TW201522337A (zh) 2013-03-12 2015-06-16 Arqule Inc 經取代之三環吡唑並－嘧啶化合物類
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
ES2685661T3 (es) 2013-11-08 2018-10-10 Ono Pharmaceutical Co., Ltd. Derivado de pirrolopirimidina
EP3102579B1 (en) 2014-02-03 2019-04-10 Cadila Healthcare Limited Heterocyclic compounds
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
US20180296561A1 (en) 2015-10-07 2018-10-18 The University Of North Carolina At Chapel Hill The Methods For Treatment Of Tumors
CN108137568A (zh) 2015-10-13 2018-06-08 日本农药株式会社 具有肟基的稠杂环化合物或其盐类及含有该化合物的农业园艺用杀虫剂以及其使用方法
WO2017083788A1 (en) 2015-11-14 2017-05-18 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
EP3373934B1 (en) 2015-11-14 2020-05-20 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
TWI753892B (zh) 2016-03-28 2022-02-01 美商英塞特公司 作為ｔａｍ抑制劑之吡咯并三嗪化合物
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
RS63928B1 (sr) 2016-07-15 2023-02-28 Ionis Pharmaceuticals Inc Jedinjenja i metode za modulaciju smn2
MX2020003375A (es) 2017-09-27 2020-08-03 Incyte Corp Sales de inhibidores de macrofagos asociados a tumores (tam).
TWI832871B (zh) 2018-06-29 2024-02-21 美商英塞特公司 Axl/mer 抑制劑之調配物

Also Published As

Publication number Publication date
AU2018342471A1 (en) 2020-04-23
PT3687996T (pt) 2022-01-21
SI3687996T1 (sl) 2022-04-29
US20220227770A1 (en) 2022-07-21
ES2904458T3 (es) 2022-04-05
AU2018342471B2 (en) 2023-08-24
TWI821200B (zh) 2023-11-11
PE20210002A1 (es) 2021-01-05
PL3687996T3 (pl) 2022-02-21
JOP20200081A1 (ar) 2020-04-30
JP2024059647A (ja) 2024-05-01
IL273579A (en) 2020-05-31
ECSP20021655A (es) 2020-07-31
MX2020003375A (es) 2020-08-03
MD3687996T2 (ro) 2022-04-30
BR112020006145A2 (pt) 2020-10-20
MA50655B1 (fr) 2021-11-30
JP2020535168A (ja) 2020-12-03
US10633387B2 (en) 2020-04-28
CR20200179A (es) 2020-11-02
LT3687996T (lt) 2022-01-10
TW201920186A (zh) 2019-06-01
HUE057190T2 (hu) 2022-04-28
CO2020005009A2 (es) 2020-05-29
US20190112313A1 (en) 2019-04-18
DK3687996T3 (da) 2022-01-10
SA520411638B1 (ar) 2024-03-28
EP3988552A1 (en) 2022-04-27
WO2019067594A1 (en) 2019-04-04
JP7504791B2 (ja) 2024-06-24
US20200347065A1 (en) 2020-11-05
CN111386273B (zh) 2024-06-14
PH12020550143A1 (en) 2020-12-07
CL2022001014A1 (es) 2022-11-18
CA3077308A1 (en) 2019-04-04
SG11202002821UA (en) 2020-04-29
KR20200088308A (ko) 2020-07-22
RS62872B1 (sr) 2022-02-28
US11104682B2 (en) 2021-08-31
EP3687996B1 (en) 2021-11-03
MA50655A (fr) 2021-06-02
CL2020000791A1 (es) 2020-09-25
CN111386273A (zh) 2020-07-07
AU2023270198A1 (en) 2023-12-14
EP3687996A1 (en) 2020-08-05
GEP20227429B (en) 2022-10-25

Similar Documents

Publication Publication Date Title
CY1124952T1 (el) Αλατα παραγωγων πυρρολοτριαζινης χρησιμα ως αναστολεις ταμ
CY1122065T1 (el) Ενωσεις αλκυλ-αμιδο-υποκατεστημενου πυριδυλιου χρησιμες ως διαμορφωτες των αποκρισεων il-12, il-23 και/η ιfναλφα
CY1126066T1 (el) Υποκατεστημενα παραγωγα θειενο[2,3-d]πυριμιδινης ως αναστολεις της μενινης-mll και μεθοδοι χρησης
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
CY1124514T1 (el) Ενωσεις [1,2,4]τριαζολο[1,5-α]πυριδινυλ-υποκατεστημενης ινδολης
CY1124476T1 (el) Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου
CY1126132T1 (el) Πυριδαζινονες ως αναστολεις parp7
CY1125289T1 (el) Αναστολεις kras g12c και μεθοδοι χρησης αυτων
CY1121188T1 (el) Αμιδο-υποκατεστημενες ετεροκυκλικες ενωσεις χρησιμες ως διαμορφωτες των αποκρισεων il-12, il-23 και/η ifn-αλφα
CY1119165T1 (el) Παραγωγα βενζιμιδαζολονης ως αναστολεις βρωμοπεδιου
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
CY1122176T1 (el) Αλατα ενος αναστολεα κινασης υποδοχεα επιδερμικου αυξητικου παραγοντα
CY1110583T1 (el) Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων
CY1117287T1 (el) Πυρρολιδινονη ως αναστολεις metap-2
CY1125017T1 (el) Ετεροκυκλυλαμινο-υποκατεστημενες τριαζολες ως ρυθμιστες της πρωτεϊνικης κινασης που σχετιζεται me rho
CY1108254T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
ECSP12006041A (es) Derivados de pirazolopiridina
CY1118371T1 (el) Αναστολεις του iap
CL2021002656A1 (es) Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso.
CY1124751T1 (el) Συνδυαστικες αγωγες οι οποιες περιλαμβανουν χορηγηση 1η-πυραζολο[4,3-b]πυριδινων
CY1122423T1 (el) Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1
UY37551A (es) Activador de nrf2
CY1123744T1 (el) Παραγωγα πυριδινυλιου, φαρμακευτικες συνθεσεις και χρησεις αυτων ως αναστολεων aoc3
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
CY1124702T1 (el) Μεθοδοι χρησης για παραγωγα τριυποκατεστημενου βενζοτριαζολιου ως αναστολεις διυδροοροτικης οξυγονασης